Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate-specific antigen

Clinical Chemistry

Volumn 43, Issue 7, 1997, Pages 1203-1208

  Woodrum, David L ^a   French, Chester M ^a   Hill, Timothy M ^a   Roman, Steven J ^a   Slatore, Harold L ^a   Shaffer, Jennifer L ^a   York, Lisa G ^a   Eure, Kathy L ^a   Loveland, Kathleen G ^a   Gasior, Gail H ^a   Southwick, Paula C ^a   Shamel, L Blair ^a  

^a Hybritech Incorporated   (United States)

Author keywords

Prostate cancer; Tumor markers

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; CROSS REACTING ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALIBRATION; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DILUTION; HUMAN; HUMAN CELL; IMMUNOASSAY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RELIABILITY;

EID: 8544273195     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.7.1203     Document Type: Article

References (26)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of human prostate specific antigen. Invest Urol 1976;17:159-63.
2. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz JS, Leong SS, Valenzuela L, et al. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst 1981;66:37-42.
3. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 1989;161:1151-9.
4. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang T, Wolfert R, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45: 729-44.
5. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
6. Catalona WJ, Ritchie J, Ahmann FK, Hudson M, Scardino P, Flanigan R, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
7. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
8. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
9. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
10. Luderer A, Chen Y, Soriano T, Kramp W, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46: 187-94.
11. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
12. Chen Y, Luderer A, Theil R, Carlson G, Cuny C, Soriano T. Using proportions of free to total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996;47:518-24.
13. Prestiagiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996;156:350-4.
14. Elgamal AA, Cornillie F, Van Poppel H, Van de Doore WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant T1c prostate cancer. J Urol 1996;156:1042-9.
15. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Eisen M, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 1996;7(Suppl):30-4.
16. Semjonow A, Burkhard B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate 1996;7(Suppl): 3-18.
17. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996;42:1026-33.
18. Fortunate A, Dorizzi RM, Marchi G, Cocco C, Davini A. fPSA/tPSA ratios obtained using nine commercial assays [Abstract]. Clin Chem 1996;42:5268.
19. Wang TJ, Hill T, Norton K, Sokoloff R, Frankenne F, Rittenhouse HG, Wolfert RL. Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate 1996;28:10-6.
20. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen. J Urol 1990;144:1523-6.
21. Berger TS, Ivor LP, inventors. Hybritech Inc., assignee. US patent 5,242,802, 1993.
22. Loveland K, Southwick P, Ratliff T, Richey J, D'Agostino D, Tanasijevic M, et al. Hybritech Tandem®-R free PSA assay performance [Abstract]. Clin Chem 1996;42:S255.
23. French CM, Eure KL, Eguilos M, Woodrum DL. Stability of free PSA in commercial controls [Abstract]. Clin Chem 1996;42:S255.
24. Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost-effective method for detection of hook effect in tumor marker assays [Letter]. Clin Chem 1993;39:695-6.
25. Woodrum DL, French CM, Shamel LB. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions. Urology 1996;48(Suppl):33-9.
26. 1-antichymotrypsin in blood samples. Urology 1996;48(Suppl):81-7.